|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
DNAtriX, Inc.
| | | Phone: | (832) 930-2401 | Fax: | (713) 715-6826 | Year Established: | 2005 | Main Contact: | Frank Tufaro, Ph.D., CEO | | Other Contacts: | Brett Ewald, Ph.D., VP, Development Erin Mitchell, Ph.D., VP, Manufacturing Imre Kovesdi, Ph.D., Senior VP, Research Joan Robbins, Ph.D., VP, Translational Research Imran Alibhai, Ph.D., Senior VP, Business development Brian Mooney, MBA, CFO Joanna Peterkin, MD, MS, Acting CMO
| | Company Description | DNAtrix's initial focus is on glioblastoma, a devastating brain tumor that is resistant to conventional therapies. DNAtrix’s lead product, DNX-2401, is a modified common cold virus that targets and kills cancer cells selectively. DNX-2401 is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, with high unmet medical need. The company’s pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient’s immune system to trigger an aggressive anti-tumor T-cell response . | |
|
|
|
|
|